Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-045297
Filing Date
2025-03-26
Accepted
2025-03-26 16:30:22
Documents
20
Period of Report
2025-03-26

Document Format Files

Seq Description Document Type Size
1 DEF 14A atos-20250326.htm   iXBRL DEF 14A 847223
2 GRAPHIC img97312702_0.jpg GRAPHIC 3754
3 GRAPHIC img97312702_1.jpg GRAPHIC 4280
4 GRAPHIC img97312702_2.jpg GRAPHIC 3754
5 GRAPHIC img97312702_3.jpg GRAPHIC 270972
6 GRAPHIC img97312702_4.jpg GRAPHIC 275604
7 GRAPHIC img97312702_5.jpg GRAPHIC 399244
8 GRAPHIC img97312702_6.jpg GRAPHIC 418333
  Complete submission text file 0000950170-25-045297.txt   5196181

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atos-20250326.xsd EX-101.SCH 13532
22 EXTRACTED XBRL INSTANCE DOCUMENT atos-20250326_htm.xml XML 389711
Mailing Address 10202 5TH AVENUE NE SUITE 200 SEATTLE WA 98125
Business Address 10202 5TH AVENUE NE SUITE 200 SEATTLE WA 98125 206.588.0256
ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings)

EIN.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-35610 | Film No.: 25773685
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)